|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer.
|
25460499 |
2014 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of miR-373 were inversely correlated with Rab22a protein levels in human EOC tissues.
|
25460499 |
2014 |
|
Malignant tumor of colon
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Based on these results, we conclude that expression of hsa-miR-373 is down-regulated by aberrant methylation in colon cancer and that this miRNA may function by regulating expression of the oncogene RAB22A.
|
21785829 |
2011 |
|
Colon Carcinoma
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Based on these results, we conclude that expression of hsa-miR-373 is down-regulated by aberrant methylation in colon cancer and that this miRNA may function by regulating expression of the oncogene RAB22A.
|
21785829 |
2011 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, Rab22A reversal downregulated the inhibitory effect of miR-520b. miR-520b expression was downregulated in NSCLC, which was negatively correlated with lymph node metastasis and TNM staging. miR-520b targeted on Rab22A to work as a tumor suppressor, inhibiting tumor proliferation and metastasis.
|
30402147 |
2018 |
|
Hepatitis B
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, we also showed that inhibition of Rab22a, one of the targets of miR-204, also suppressed intracellular and extracellular HBV DNA expression in HepG2.2.15.7 cells.
|
30042818 |
2018 |
|
Adult Liver Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Rab22a is overexpressed in different cancer types, including liver cancer, malignant melanoma, ovarian cancer and osteosarcoma.
|
28433697 |
2017 |
|
Malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that Rab22a enhances recycling of CD147, which is required for lung cancer cell migration and invasion,and targeting CD147 recycling may be a rational strategy for lung cancer therapy.
|
28433697 |
2017 |
|
Liver and Intrahepatic Biliary Tract Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Rab22a is overexpressed in different cancer types, including liver cancer, malignant melanoma, ovarian cancer and osteosarcoma.
|
28433697 |
2017 |
|
Malignant neoplasm of liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Rab22a is overexpressed in different cancer types, including liver cancer, malignant melanoma, ovarian cancer and osteosarcoma.
|
28433697 |
2017 |
|
Carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that Rab22a enhances recycling of CD147, which is required for lung cancer cell migration and invasion,and targeting CD147 recycling may be a rational strategy for lung cancer therapy.
|
28433697 |
2017 |
|
Primary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that Rab22a enhances recycling of CD147, which is required for lung cancer cell migration and invasion,and targeting CD147 recycling may be a rational strategy for lung cancer therapy.
|
28433697 |
2017 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of RAB22A by oe-RAB22A was able to partially reverse the miR-204-mediated suppression of RCC tumor progression.
|
26883716 |
2016 |
|
Metastatic melanoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we found that RAB22A mRNA expression was significantly upregulated in melanoma tissues (including 60 primary melanomas and 84 metastatic melanomas) compared to benign nevi (n = 20), which were significantly higher in metastatic melanoma tissues than primary tissues.
|
27690221 |
2016 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overexpression of RAB22A by oe-RAB22A was able to partially reverse the miR-204-mediated suppression of RCC tumor progression.
|
26883716 |
2016 |
|
Lyme Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We now show that Borrelia internalization by primary human macrophages involves uptake and compaction into Rab22a-positive phagosomes that are in close contact with Rab5a-positive vesicles.
|
26344766 |
2015 |
|
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results uncovered that miR-204-5p acts as a tumor suppressor in GC through inhibiting USP47 and RAB22A.
|
25429829 |
2015 |
|
Carcinogenesis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Take together, our results demonstrated that miR-203 act as a tumor suppressor miRNA through regulating RAB22A expression and suggested its involvement in osteosarcoma progression and carcinogenesis.
|
26382657 |
2015 |
|
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results uncovered that miR-204-5p acts as a tumor suppressor in GC through inhibiting USP47 and RAB22A.
|
25429829 |
2015 |
|
Epithelial ovarian cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of miR-373 were inversely correlated with Rab22a protein levels in human EOC tissues.
|
25460499 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate for the first time that miR-204-5p acts as a tumor suppressor in colorectal cancer through inhibiting RAB22A and reveal RAB22A to be a new oncogene and prognostic factor for colorectal cancer.
|
25294901 |
2014 |